Analystreport

Rubius Therapeutics, Inc. (NASDAQ: RUBY) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.

Rubius Therapeutics, Inc.  (RUBY) 
Last rubius therapeutics, inc. earnings: 3/12 07:00 am Check Earnings Report